Semaglutide vs Empagliflozin
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two types of drug that people with type 2 diabetes often choose between, and one of the few pairs on this site where they have been tested directly against each other. Each has heart outcome data of its own. The trial below measured neither.
- Semaglutide people
- 42,363
- Semaglutide nulls
- 2
- Empagliflozin people
- 16,738
- Empagliflozin nulls
- 1
Dose
Approved titration: 0.25, 0.5, 1, 1.7 and 2.4 mg
0.25, 0.5, 1, 1.7 and 2.4 mg
The approved semaglutide ladder, in mg.
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for type 2 diabetes. It is also approved to cut the risk of dying from heart disease in adults with type 2 diabetes who already have heart disease, for heart failure whether the heart pumps weakly or normally, and for chronic kidney disease. Not approved for ageing, longevity or healthspan.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke.
Column B
EmpagliflozinEmpagliflozin (sodium-glucose cotransporter 2 inhibitor)
A diabetes pill that also protects the heart and kidneys. Four big studies in more than 23,000 sick people found fewer deaths and fewer hospital stays. In the biggest diabetes study, 5.7 percent died on the drug and 8.3 percent on a dummy pill, 32 percent fewer deaths. Nobody has tested it for ageing in people. The whole ageing case is one mouse study from one lab, where male mice lived 5.9 percent longer.
These two were tested against each other in the same trial
One trial gave people each of them. This is not us lining up two separate records.
Counting everyone as assigned, HbA1c fell 1.3 percent on semaglutide pills against 0.9 percent on empagliflozin at week 26. That is a gap of 0.4 percentage points, and it was clear. Better weight loss was not confirmed at week 26. At week 52, counting only people who stayed on their drug, weight fell 4.7 kg against 3.8 kg, and that gap was also clear. Stomach and gut side effects were more common on semaglutide pills.
What the trial was
A 52 week study. Everyone knew which drug they got. 822 adults with type 2 diabetes not controlled on metformin got once daily semaglutide pills, 14 mg (412 people), or empagliflozin 25 mg (410). The main measure was the change in HbA1c at week 26. Body weight was the key second measure. Each was counted two ways: everyone as assigned, and only people who stayed on their drug.
What the authors concluded
The authors conclude that semaglutide pills beat empagliflozin at lowering HbA1c at 26 weeks but not at cutting body weight. By week 52, counting only people who stayed on their drug, semaglutide pills clearly beat it on both.
Where this result is weak
Everyone knew which drug they got, it lasted one year, and it measured blood markers. The weight result did not clear its bar at the main time point, which is easy to miss when the 52 week figure is quoted alone. It tested semaglutide as a pill, not the shot, and it was paid for by Novo Nordisk. Empagliflozin's main claim is protecting the heart and kidneys over years, and this trial measured none of that.
Side by side, on the facts we can check
| What we compare | Semaglutide | Empagliflozin |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | FDA approved for type 2 diabetes. It is also approved to cut the risk of dying from heart disease in adults with type 2 diabetes who already have heart disease, for heart failure whether the heart pumps weakly or normally, and for chronic kidney disease. Not approved for ageing, longevity or healthspan. |
| Half-life | ~7 days | About 12 hours. |
| Molecular weight | 4,113.6 Da | 450.9 Da |
| How it works | It switches on the GLP-1 receptor, a switch on cells that normally answers a gut hormone after you eat. That makes the body release insulin when blood sugar is high. It holds back glucagon, a hormone that raises blood sugar. It slows how fast the stomach empties. It also acts on the part of the brain that runs hunger, so people eat less. | It blocks a pump in the kidney called SGLT2. That pump normally pulls sugar back out of the urine. With it blocked, the sugar leaves the body. The heart and kidney benefit is bigger and faster than lower blood sugar alone explains. Nobody fully knows why. The leading ideas: less fluid in the blood, so the heart works less hard. Lower pressure inside the kidney's filters. The heart switching to a different fuel called ketones. And less salt build-up inside heart cells. The mouse work adds more ideas, like energy-sensing switches in cells and changes in gut bacteria. Those come from mice, which is a much weaker kind of evidence than the big human studies. |
| Studies in people | 15 | 4 |
| Evidence | Strong: 12 completed trials, 42,363 people given it | Strong: 3 completed trials, 16,738 people given it |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Semaglutide and Empagliflozin?
Semaglutide: A once a week shot for type 2 diabetes and weight loss. It is approved, and big studies show it also lowers the risk of heart attack and stroke. Empagliflozin: A diabetes pill that also protects the heart and kidneys. Four big studies in more than 23,000 sick people found fewer deaths and fewer hospital stays. In the biggest diabetes study, 5.7 percent died on the drug and 8.3 percent on a dummy pill, 32 percent fewer deaths. Nobody has tested it for ageing in people. The whole ageing case is one mouse study from one lab, where male mice lived 5.9 percent longer.
Which has stronger research evidence, Semaglutide or Empagliflozin?
Each compound gets a band worked out from facts we counted, with the math shown. Semaglutide is Strong (12 completed trials, 42,363 people given it). Empagliflozin is Strong (3 completed trials, 16,738 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Semaglutide and Empagliflozin FDA-approved?
Semaglutide: FDA-approved (Ozempic and Rybelsus for type 2 diabetes; the Wegovy shot, the Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Empagliflozin: FDA approved for type 2 diabetes. It is also approved to cut the risk of dying from heart disease in adults with type 2 diabetes who already have heart disease, for heart failure whether the heart pumps weakly or normally, and for chronic kidney disease. Not approved for ageing, longevity or healthspan..
Related posts
Blog articles that cover Semaglutide or Empagliflozin, newest first.
- Dispatch / Sep 27, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 27, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 27, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.